TY - JOUR
T1 - Navigating systemic therapy in advanced thyroid carcinoma
T2 - From standard of care to personalized therapy and beyond
AU - Rao, Sarika N.
AU - Cabanillas, Maria E.
N1 - Publisher Copyright:
© 2018 Endocrine Society.
PY - 2018/10
Y1 - 2018/10
N2 - Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable outcomes with the standard therapy. However, those that persist, recur, or metastasize are associated with a worse prognosis. Targeted therapy with kinase inhibitors has shown promise in advanced cases of thyroid cancer, and currently five drug regimens are approved for use in clinical practice in the treatment of differentiated, medullary, and anaplastic thyroid cancer, with more options in the pipeline. However, one of the greatest dilemmas is when and how to initiate one of these drugs, and this is discussed herein.
AB - Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable outcomes with the standard therapy. However, those that persist, recur, or metastasize are associated with a worse prognosis. Targeted therapy with kinase inhibitors has shown promise in advanced cases of thyroid cancer, and currently five drug regimens are approved for use in clinical practice in the treatment of differentiated, medullary, and anaplastic thyroid cancer, with more options in the pipeline. However, one of the greatest dilemmas is when and how to initiate one of these drugs, and this is discussed herein.
KW - Anaplastic thyroid cancer
KW - BRAF inhibitors
KW - Differentiated thyroid cancer
KW - Immunotherapy
KW - Kinase inhibitors
KW - Medullary thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=85058051141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058051141&partnerID=8YFLogxK
U2 - 10.1210/js.2018-00180
DO - 10.1210/js.2018-00180
M3 - Article
C2 - 30250937
AN - SCOPUS:85058051141
SN - 2472-1972
VL - 2
SP - 1109
EP - 1130
JO - Journal of the Endocrine Society
JF - Journal of the Endocrine Society
IS - 10
ER -